Physician profile
Mohammad Akhtaruzzaman
NPI 1891840625
$2,913.39
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $314 · 2021: $89.53 · 2022: $559 · 2023: $1,023 · 2024: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $941.82 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $624.41 | 2019-2024 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $224.97 | 2019-2023 | Dupixent |
| Grifols USA, LLC | $209.44 | 2019-2023 | Xembify, Prolastin-C Liquid |
| Genzyme Corporation | $193.98 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $174.77 | 2019-2022 | |
| Pharming Healthcare, INC. | $117.60 | 2022-2023 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $87.08 | 2022-2023 | Cuvitru |
| Amgen INC. | $80.32 | 2022-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $66.88 | 2019-2020 | |
| Optinose US, INC. | $50.08 | 2020-2021 | |
| Genentech USA, INC. | $49.22 | 2019 | |
| Abbvie INC. | $43.60 | 2023 | Rinvoq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.67 | 2019 | |
| Hikma Pharmaceuticals USA | $17.31 | 2023 | Ryaltris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $14.24 | 2024 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Akhtaruzzaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.